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D
oes an intensive reduction in blood pressure (BP) induced by lifestyle measures and drug treatment confer a benefit or, conversely, an added risk to patients? Following the early observations by Cruickshank et al, 1 several studies addressed the paradoxical increase in the risk of major cardiovascular events and death in hypertensive patients achieving very low BP values (the socalled J-curve phenomenon). However, placebo-controlled trials did not show any significant increase in the risk of cardiovascular events, with perhaps a rise in the risk of noncardiovascular mortality, in association with very low levels of achieved BP. 2 Thus, it became crucial to uncouple the BP-lowering effect of antihypertensive treatment from the impact of several potential conditions associated with low BP and adverse outcome (reverse causality). Among these conditions, cancer and congestive heart failure may be potent inducers of hypotension and poor prognosis, regardless of the antihypertensive treatment to which patients are exposed. Unfortunately, adjustment for confounders had not always been addressed satisfactorily in studies focusing on the J-curve phenomenon.
In some analyses, the J-curve phenomenon occurred mostly in patients with coronary artery disease. [1] [2] [3] An excessive reduction in diastolic BP could theoretically lead to coronary hypoperfusion, in particular, in the presence of significant stenosis. Because most of these studies date back to an era 1, 2 in which coronary reperfusion procedures were not common, we conducted a post hoc analysis of the ONTARGET study (Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial) in ≈19 000 patients with coronary artery disease exposed to modern anti-ischemic strategies, including coronary reperfusion. 4 A strong linear relation was found ( Figure) between BP changes during the study and the risk of stroke, whereas even a marked reduction in BP, on the order of 30 to 35 mm Hg, was not associated with any significant increase in the risk of myocardial infarction. 4 A more recent analysis of the ONTARGET database, which confirmed the absence of a J-curve for myocardial infarction and stroke, found a J-shaped relationship for all-cause death, cardiovascular death, and heart failure. 5 Unfortunately, in this analysis, known confounders were not modeled as time-varying covariables, and the authors concluded that "it is not possible to rule out some effect of reverse causality" to explain their findings. 5 In addition to careful adjustment for potential sources of reverse causality, other approaches are warranted to better clarify whether an intensive BP reduction may play a direct role in the pathogenesis of the J-curve. In this issue of Circulation, Kalkman and colleagues present an interesting and timely post hoc analysis of the pooled database of the SPRINT (Systolic Blood Pressure Intervention Trial) 6 and ACCORD (Action to Control Cardiovascular Risk in Diabetes) 7 trials, which randomly allocated patients at high vascular risk to an intensive (systolic BP <120 mm Hg) or conven-
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Intensive Treatment and the J-Curve in the SPRINT Trial (Systolic Blood Pressure Intervention Trial) tional (systolic BP <140 mm Hg) target. 8 The analysis included 13 946 patients who contributed 1014 major cardiovascular events and 502 deaths during a median follow-up of 3.3 years. 8 Kalkman and coworkers used an innovative methodological approach to model the excess risk of cardiovascular disease or death and the difference between the achieved BP in relation to the randomized BP target. In other words, by dealing with 2 groups randomly assigned to markedly different BP targets (140 versus 120 mm Hg), these authors had the opportunity to investigate whether the advantage of a more intensive versus a less intensive approach persisted at any level of the difference, in either direction, between the intended BP target (140 or 120 mm Hg) and the BP levels actually achieved at follow-up. It is noteworthy that an identical shape of the J-curve was noted for both BP targets, and a nadir for cardiovascular events and all-cause mortality occurred just below the systolic BP target. 8 The advantage of the intensive treatment group persisted at any level of the difference between the intended target and the achieved BP levels. 8 These data suggest that if 2 patients achieve identical low values of BP during treatment, prognosis is expected to be better in the patient actually targeted to achieve lower values. Conversely, the outcome might be worse in the patient randomly assigned to a higher BP target, because low values in this case possibly reflect masked or unmasked confounders linked to a poorer outcome. Indeed, the patients in SPRINT in the lowest systolic BP stratum were older, had a higher body mass index, were more frequently smokers, and had a higher frequency of diabetes mellitus and prior cardiovascular events. 6 Thus, the alignment of the J-curve with the systolic BP target suggests that the reported associations between achieved BP, mortality, and other vascular outcomes are independent of the achieved BP level. Thus, physicians should not be reluctant in lowering BP in their patients because of an expected detrimental effect of BP reduction on death or major cardiovascular events. Rather, they should carefully monitor the possible occurrence of other adverse events linked to BP lowering, including syncope, renal impairment, and electrolyte disturbances, which were significantly more common in patients randomly assigned to the more intensive BP target. 6 Overall, the benefits of a more intensive BP reduction largely outweigh the risks of adverse events. In a recent meta-analysis of strategy trials, we showed that Adjusted hazard ratio for systolic and diastolic blood pressure changes from baseline. Results by multivariable Cox regression with restricted cubic splines and 3 knots for systolic and diastolic blood pressure changes. Reprinted from Verdecchia et al a more intensive strategy significantly reduced stroke by 20%, myocardial infarction by 15%, heart failure by 25%, and cardiovascular death by 18%. 9 In keeping with our findings, a recent network meta-analyses concluded that an achieved systolic BP <120 mm Hg was associated with the greatest reduction in the risk of cardiovascular disease. 10 If the interpretation of this evidence is correct, future hypertension guidelines should reinforce the message that lower BP targets are not dangerous, because the higher risk of major cardiovascular events or death observed at low achieved BP is not a direct consequence of intensive BP lowering.
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